Abstract Antiestrogen therapy has been used successfully to prolong disease-free and overall survival of ER positive breast cancer patients. However, 50% of patients with ER? tumors fail to respond to such therapy or eventually acquire resistance to endocrine therapy, resulting in tumor progression and mortality. It is imperative, therefore, to understand the mechanisms that lead to hormone refractory breast cancer in order to develop therapeutics that can modulate the resistance to antiestrogen therapy. The protease, ADAM12, can be detected in the urine of breast cancer patients and its levels correlate with disease status, stage, and cancer risk. Within the context of this study, the authors have investigated the role of the two distinct isoforms of ADAM12 in breast tumor cell proliferation and as potential mediators of endocrine resistance. Using stable clones of ADAM12-overexpressing MCF-7 cells, the authors analyzed proliferation rates of these ER? breast tumor cells both in estrogen-depleted medium and in the presence of the antiestrogens, tamoxifen, and ICI 182,780. Acquired estrogen resistance in these cells was analyzed using phospho-RTK analysis. Upregulation and phosphorylation of proteins were detected via immunoprecipitation and immunoblotting. EGFR and MAPK inhibitors were used to explore the mechanism of acquired estrogen resistance in breast tumor cells. It was observed that overexpression of the two isoforms, transmembrane ADAM12-L, and secreted ADAM12-S, in breast tumor cells promoted estrogen-independent proliferation. In ADAM12-L-expressing cells, estrogenindependence was a direct result of increased EGFR expression and MAPK activation, whereas, the mechanism in ADAM12-S-expressing cells may be enhanced IGF-1R signaling. The importance of the EGFR signaling pathway in the estrogen-independent growth of ADAM12-L expressing cells was highlighted by the effect of EGFR inhibitors AG1478 and PD15035 or MAPK inhibitor U0126, each of which abolished the antiestrogen resistance in these cells. Taken together, these results demonstrate that ADAM12 isoforms confer a proliferative advantage to MCF-7 cells in the absence of estrogen stimulation, and suggest that downregulation of ADAM12 in combination with endocrine therapy may represent a useful pharmacological approach to breast cancer therapy.
Abstract Antiestrogen therapy has been used successfully to prolong disease-free and overall survival of ER positive breast cancer patients. However, 50% of patients with ER? tumors fail to respond to such therapy or eventually acquire resistance to endocrine therapy, resulting in tumor progression and mortality. It is imperative, therefore, to understand the mechanisms that lead to hormone refractory breast cancer in order to develop therapeutics that can modulate the resistance to antiestrogen therapy. The protease, ADAM12, can be detected in the urine of breast cancer patients and its levels correlate with disease status, stage, and cancer risk. Within the context of this study, the authors have investigated the role of the two distinct isoforms of ADAM12 in breast tumor cell proliferation and as potential mediators of endocrine resistance. Using stable clones of ADAM12-overexpressing MCF-7 cells, the authors analyzed proliferation rates of these ER? breast tumor cells both in estrogen-depleted medium and in the presence of the antiestrogens, tamoxifen, and ICI 182,780. Acquired estrogen resistance in these cells was analyzed using phospho-RTK analysis. Upregulation and phosphorylation of proteins were detected via immunoprecipitation and immunoblotting. EGFR and MAPK inhibitors were used to explore the mechanism of acquired estrogen resistance in breast tumor cells. It was observed that overexpression of the two isoforms, transmembrane ADAM12-L, and secreted ADAM12-S, in breast tumor cells promoted estrogen-independent proliferation. In ADAM12-L-expressing cells, estrogenindependence was a direct result of increased EGFR expression and MAPK activation, whereas, the mechanism in ADAM12-S-expressing cells may be enhanced IGF-1R signaling. The importance of the EGFR signaling pathway in the estrogen-independent growth of ADAM12-L expressing cells was highlighted by the effect of EGFR inhibitors AG1478 and PD15035 or MAPK inhibitor U0126, each of which abolished the antiestrogen resistance in these cells. Taken together, these results demonstrate that ADAM12 isoforms confer a proliferative advantage to MCF-7 cells in the absence of estrogen stimulation, and suggest that downregulation of ADAM12 in combination with endocrine therapy may represent a useful pharmacological approach to breast cancer therapy.
Keywords ADAM Á Metalloprotease Á Breast tumor proliferation Á Antiestrogen resistance Á EGFR Á Amphiregulin 
Introduction
Breast cancer is one of the most prevalent diseases in women worldwide. Estrogen receptor (ER) positive breast cancers are the most common [1] . Antiestrogens such as tamoxifen have proven very effective as first-line endocrine therapy of early and advanced breast cancers to prolong disease-free and overall survival in these patients. However, 50% of patients with ER? tumors fail to respond to these drugs and even patients who initially respond eventually acquire resistance to endocrine therapy, resulting in tumor progression and mortality [2] . This resistance does not necessarily require a loss of expression of, or mutations, in ER in these tumors. In fact, more than 60% of tamoxifen-resistant tumors continue to express ER [2] . The mechanisms of innate or acquired antiestrogen tumor resistance are complex and range from loss of, phosphorylation of, or mutations in, the ER, dysfunctional GATA-3/ FOXA1 transcriptional networks [3] , modulation of TGFb signaling by hormone-responsive miR-128a [4] and activation of other growth promoting pathways [5] [6] [7] .
There is increasing evidence that in endocrine resistant breast tumors and cell lines aberrant activation of growth factor signaling cascades can provide proliferative and survival advantages. Human ADAM12 is expressed as two alternatively spliced forms, a transmembrane form (ADAM12-L) and a secreted form (ADAM12-S) [8] . ADAM12-L and -S share high overall sequence homology differing only in the transmembrane domain (which ADAM12-S lacks) and the C-terminus. The catalytic domain of ADAM12 contains the consensus HExGHxxGxxHD zinc-binding motif and both isoforms are active proteases. ADAM12-L sheds several membrane-bound ligands including HB-EGF [9] , EGF [10] , betacellulin [10] , Notch ligand Delta-like 1 [11] and placental leucine aminopeptidase [12] . ADAM12-S can cleave IGFBP-3 and IGFBP-5 [13, 14] and degrade ECM substrates [15] . ADAM12 mRNA and protein are highly expressed in a variety of malignant tumor tissues and tumor cell lines including breast, brain, bladder, gastric, colon, lung, laryngeal, and hepatocellular carcinomas (For review see: [16] [17] [18] [19] [20] [21] [22] [23] [24] ).
ADAM12 can be detected in the urine of breast [15] and bladder [19] cancer patients and its levels have been shown to correlate with disease status, stage, and cancer risk [15, 25] . The discovery of ADAM12 as a potential biomarker for breast cancer raised the question of its relevance in human breast tumorigenesis. Recently, the authors have demonstrated that overexpression of both ADAM12-L and -S isoforms in breast tumor cells results in a significantly higher rate of tumor take and increased tumor size in an orthotopic breast tumor model [26] . In this study it was observed that the overexpression of the two isoforms, transmembrane ADAM12-L and secreted ADAM12-S, in breast tumor cells promotes estrogen-independent breast tumor cell proliferation. Within the context of this study, the authors have investigated the role of the two distinct isoforms of ADAM12 in breast tumor cell proliferation and as potential mediators of endocrine resistance. . HRP-conjugated anti-rabbit and antimouse antibodies were from Vector Biolabs (Burlingame, CA). MCF-7 and T47-D cells were obtained from American type culture collection (ATCC, Manassas, VA) and cultured as per ATCC protocols. Tamoxifen-sensitive and tamoxifen-resistant MCF-7 clones were the kind gift of Dr. Toshi Shioda and cultured as described previously [27] .
Materials and methods

Reagents
Transfection of breast cancer cells with human ADAM12-L and -S MCF-7 and T47-D cells were stably transfected with pcDNA3 plasmid encoding human full-length ADAM12-L, ADAM12-S, and ADAM12-S catmut (with a E351Q point mutation) using Amaxa Nucleofector Kit (Lonza, Walkersville, MD). Stable clones were selected based on neomycinresistant growth (G418, 0.5 mg/ml; Life Technologies, CA). ADAM12-expressing MCF-7 stable clones were selected based on significantly higher ADAM12 mRNA and protein expression as described previously [26] . Pools of ADAM12 stable clones were used for analysis of T47-D cells (Suppl. Fig. 1 ).
Immunoblotting
Cell lysates were prepared using 19 lysis buffer (Cell Signaling Technology). Serum-free CM was used for analysis of ADAM12-S and shed EGF ligands. For the analysis of EGF ligand shedding serum-free CM was concentrated 100-fold using 3 kDa cutoff filters (YM-3 Microcon, Millipore Corporation). Protein concentration of the lysates and CM was determined using the Bradford method (Biorad Laboratories, Hercules, CA). Immunoblotting and densitometric analysis was conducted as described previously [15] .
Proliferation assay
Cells (20000/well) were plated in triplicate in 24-well plates and were maintained in standard culture medium. Cells were harvested at 24, 48, and 72 h time points and counted using a coulter-counter or hemocytometer. For estrogen-depleted growth conditions, cells were cultured until *90% confluent, washed 4-6 times with phenol red free DMEM and maintained in 10% charcoal-stripped FBS containing medium. Subsequently, the cells were plated for proliferation as described above. For anti-estrogen growth studies ER antagonist tamoxifen (3 lM) and ER inhibitor ICI 182,780 (100 nM) were added at 0 h. For EGFR inhibition studies the EGFR inhibitor AG1478 (10 lM), PD15035 (1 lM), and MAPK inhibitor U0126 (10 lM) were added in combination with ICI 182,780.
RT-PCR analysis
Total RNA was extracted from cells using the RNAeasy Qiagen Kit according to the manufacturer's protocol (Qiagen, Germantown, MD). cDNA was prepared by reverse transcription from 1 lg of total RNA using the Superscript III Reverse Transcriptase Kit (Invitrogen). Forward and reverse primers were designed as follows:
. GAPDH expression was used to normalize cDNA levels. Real time RT-PCR was conducted on a MJ Research DNA Engine Opticon 2 (Biorad Laboratories) using iQ TM SYBR Ò Supermix (Biorad Laboratories, Hercules, CA).
Receptor tyrosine kinase (RTK) phosphorylation analysis
Phosphorylated growth factor receptor tyrosine kinases (RTKs) were detected using the Proteome Profiler Array Kit (R & D Systems). WT MCF-7 cells and ADAM12-L and -S clones were cultured until *70% confluent. Cells were starved overnight in serum-free medium and activated for 15 min with 10% serum-containing medium. RTK arrays were then incubated with cell lysates (300 lg total protein) and subsequently dot blots were developed according to manufacturer's protocol. Densitometric measurement of dot blots was conducted as described previously [15] .
Statistical analysis
Results for proliferation and inhibition assays are reported as mean ± SD of at least three-independent experiments. Differences between experimental groups were statistically analyzed using the Mann-Whitney test. P B 0.05 were considered to be statistically significant.
Results
ADAM12 expression promotes higher proliferation rates in breast tumor cells
In order to explore the role of the protease ADAM12 in breast tumorigenesis, the authors selected a breast tumor cell line that expresses low levels of this metalloprotease, MCF-7 and engineered stable clones for overexpression studies [26] . Both WT MCF-7 and stable ADAM12 overexpressing MCF-7 clones demonstrated comparable proliferation rates (Fig. 1a, left panel) in the presence of estrogen. In contrast, when estrogen was depleted from the medium (using charcoal-stripped FBS and phenol red-free DMEM), the ADAM12-S and -L stable clones appeared to proliferate at a significantly faster rate than did the WT MCF-7 cells (Fig. 1a, right panel) . DNA synthesis, as measured by [ 3 H]thymidine uptake assay, indicated that both ADAM12-L and -S clones had slightly and moderately higher rates of DNA synthesis, respectively, as compared to the WT MCF-7 cells, however, the differences did not approach significance (data not shown). Transcript and protein levels of ERa remained unchanged, indicating that the acquired estrogen-independent growth of the ADAM12-expressing cells was not accompanied by a loss of ERa expression (Fig. 1b) .
Since overexpression of the ADAM12 isoforms appeared to promote estrogen-independent growth in MCF-7, the authors next asked whether ADAM12-expressing cells were resistant to antiestrogen treatment. ADAM12-L and -S-expressing clones proliferate at significantly faster rates than WT MCF-7 in the presence of the antiestrogen compounds tamoxifen (3 lM), or ER inhibitor ICI 182,780 (100 nM) (Fig. 2a) . Whereas, WT MCF-7 cells displayed C50% growth inhibition when cultured in the presence of tamoxifen as previously reported [28] , ADAM12-expressing MCF-7 clones displayed significantly lower growth inhibition under the same conditions (Fig. 2b) , although ERa expression was maintained in these cells (Fig. 2c) . Similarly, when cultured in the presence of ICI 182,780, a compound that completely ablates ERa expression (Fig. 2c) , MCF-7 cells display C75% growth inhibition whereas ADAM12-L and -S-expressing cells were inhibited significantly less (Fig. 2b) . Taken together, these data indicate that ADAM12 expression appears to protect MCF-7 cells from antiestrogen treatment and allows these cells to proliferate in the absence of ERa signaling.
ADAM12 isoforms induce estrogen-independent growth of breast tumor cells via upregulation of alternative pathways
In order to define the mechanism by which ADAM12-overexpression provides a proliferative advantage to breast tumor cells, the authors asked whether switching to alternate growth pathways might facilitate estrogen-independent growth in these cells. The phospho-receptor tyrosine kinase (pRTK) profile of serum-activated WT MCF-7 and ADAM12-overexpressing clones was determined. PhosphoEGFR and pIGF-1R levels increased 1.5-2.0-fold in ADAM12-S and -L clones, respectively, compared to WT MCF-7 cells (Fig. 3a) . Phosphorylation of other receptors of the ErbB family, such as ErbB2, ErbB3 or ErbB4 was not detected. In order to confirm these findings, the effect of IGF-1 or EGF treatment on cultured cells was tested. Cell lysates were immunoprecipitated with anti-IGF-1R or anti-EGFR antibodies and probed with a pan-phosphotyrosine antibody. Increased phosphorylation of IGF-1R was observed in both ADAM12-S and -L expressing cells as compared to WT MCF-7 cells (Fig. 3b, upper panel) , whereas increased pEGFR levels were detected only in the ADAM12-L-expressing cells (Fig. 3c) . Interestingly, levels of pMAPK, a downstream mediator of IGF-1R, were also preferentially elevated in ADAM12-S-expressing clones as compared to WT MCF-7 (Fig. 3b, lower panel) . These data, combined with the fact that pIGF-1R levels are higher in ADAM12-S-expressing breast tumor cells, suggest that ADAM12-S expression may stimulate signaling via the IGF-1/IGF-1R pathway and thereby increase proliferation.
Since pEGFR was selectively upregulated in response to ADAM12-L expression, the authors analyzed the expression of EGFR family members in these cells. ADAM12-L expression resulted in significantly higher levels of EGFR protein and transcript as compared to WT (Fig. 3d, e) . Though Her3 expression was slightly elevated in the ADAM12-L clones, Her2 and Her4 expression remained unchanged. Upregulation of EGFR expression also correlated with ADAM12 overexpression in T47-D cells, another ERa positive breast cancer cell line. Analysis of WT T47-D and stable clone pools of ADAM12-expressing cells indicated that EGFR protein was significantly upregulated in response to ADAM12 expression whereas ERa levels remained unchanged (Suppl. Fig. 1d ). EGF stimulation resulted in higher pEGFR levels in ADAM12-L-expressing clones as compared to WT MCF-7 cells (Fig. 3f) . A similar increase in EGFR mRNA and/or protein expression or activation was not observed in the ADAM12-S-expressing clones, where levels remained comparable to WT MCF-7 cells (data not shown). Taken together, the upregulation in EGFR and MAPK activation in ADAM12-L-expressing MCF-7 cells suggests that, in contrast to ADAM12-S, ADAM12-L expression may stimulate signaling via the EGFR/MAPK pathway.
ADAM12-L expression stimulates amphiregulin shedding in breast tumor cells
Based on the previously reported sheddase function of ADAM12, the authors asked whether the increase in EGFR expression in this model could be a consequence of increased EGF ligand shedding. The authors analyzed serum-free conditioned media (CM) for the presence of a panel of EGFR ligands, HB-EGF, EGF, TGFa, and amphiregulin (AR) (Fig. 4a) . Conditioned media from ADAM12-L-and -S-expressing clones had significantly (10-40-fold) higher levels of free AR as compared to WT MCF-7 (Fig. 4a, b) . This increased shedding of AR in response to ADAM12 expression was not limited to MCF-7 cells. In fact, CM from T47-D cells expressing ADAM12 isoforms also had higher AR levels as compared to control cells (Fig. 4c) . This is the first report of ADAM12-mediated AR shedding in breast tumor cells. The increase in AR shedding was a function of ADAM12 expression and not due to a compensatory expression of other proteases such as ADAM9, ADAM10, ADAM15 or ADAM17, since the expression of these remained unchanged (Suppl. Fig. 2a) . The authors did not observe an increase in AR or EGF mRNA expression levels in ADAM12-expressing MCF-7 clones (Suppl. Fig. 2b) . Although, HB-EGF expression appeared to be upregulated in these cells the authors did not detect a concomitant increase in HB-EGF shedding in these cells (Fig. 4a ).
EGFR and MAPK inhibition results in loss of estrogenindependent growth in ADAM12-expressing breast tumor cells
Finally, to test the hypothesis that ADAM12 expression may stimulate EGFR and MAPK signaling and thereby increase cell proliferation and estrogen-independent growth, the authors analyzed the effects of EGF receptor-kinase or Comparative expression of EGF receptor family members in ADAM12-L clones (d). ADAM12-L-expressing clones had increased protein expression of EGFR and HER3 (ErbB3), whereas HER2 (ErbB2) and HER4 (ErbB4) levels remained unchanged (d). EGFR transcript levels were also upregulated in ADAM12-L clones as compared to WT MCF-7 (e). pEGFR levels were higher in ADAM12-L-expressing clones as compared to WT MCF-7, GAPDH is used as a loading control (f) MAPK inhibition on proliferation of ADAM12-expressing clones and WT MCF-7. MCF-7 cells displayed C75% growth inhibition when treated with ICI 182,780, whereas ADAM12-L and -S-expressing cells were inhibited significantly less (*43%; P B 0.01 and *31%; P B 0.001) despite the fact that ICI 182,780 treatment completely abrogated ERa protein expression (Fig. 2c) . Treatment of ADAM12-L-expressing cells with the EGFR inhibitor AG1478 (10 lM) or the selective EGFR inhibitor, PD15035 (1 lM) or the MAPK inhibitor U0126 (10 lM) in combination with the ER inhibitor ICI 182,780, resulted in 78-90% growth inhibition in the ADAM12-L-expressing clones and, therefore, a complete loss of resistance to the estrogen inhibitor ICI 182,780 (Fig. 5a) . Similar results were observed for ADAM12-S-expressing clones, where AG1478 and U0126 treatment led to 61-82% growth inhibition in response to ICI 182,780 treatment. Interestingly, PD15035 treatment resulted in only 61 ± 5% inhibition in these cells (Fig. 5a) , whereas, in ADAM12-L-expressing cells PD15035 treatment resulted in 83 ± 3% growth inhibition (Fig. 5a ). Since PD15035 used at lower concentrations is a specific inhibitor of EGFR [29] , these data suggest that ADAM12-S-expressing cells may not be as susceptible to EGFR inhibition as are ADAM12-L-expressing cells. Treatment of WT MCF-7 cells with AG1478 or U0126 alone resulted in 30 ± 5% and 45 ± 5% inhibition, whereas treatment of ADAM12-L-expressing cells with AG1478 or U0126 alone resulted in 10 ± 5% and 35 ± 5% inhibition, respectively (data not shown). In order to determine the effectiveness of the inhibitors used in the cell proliferation assay, the authors analyzed MAPK levels. As expected, U0126 treatment resulted in significantly lower levels of pMAPK in ADAM12-expressing and WT MCF-7 cells (Fig. 5b) . In addition, pMAPK levels were also downregulated when ADAM12-expressing clones and WT-MCF-7 cells were treated with the EGFR inhibitors PD15035 and AG1478 (Fig. 5c ). Taken together, these results indicate that the increased proliferation observed in ADAM12-L and -S clones is likely due to the activation of alternate growth pathways that allows the cells to survive and proliferate even in the absence of estrogen signaling.
ADAM12 expression is upregulated in tamoxifenresistant breast tumor cells
Having demonstrated that ADAM12-expressing MCF-7 cells are resistant to growth inhibition in the presence of antiestrogens such as tamoxifen and ICI 182,780, the authors analyzed expression of the two isoforms of ADAM12 in tamoxifen-resistant breast tumor cells. Since the proliferation of MCF-7 cells is dependent on estrogen, this cell line has been widely used to explore mechanisms of clinical endocrine therapy resistance. Using tamoxifenresistant and tamoxifen-sensitive clones of MCF-7 previously established by Coser et al. [27] , it was found that basal levels of ADAM12 expression are not significantly different between tamoxifen-resistant and -sensitive MCF-7 clones. However, in the presence of tamoxifen (1 lm), ADAM12-S expression was significantly higher in tamoxifen-resistant clones MCF-T17 (15-fold; P B 0.05) and MCF-T52 (7.5-fold; P B 0.05) (Fig. 6a) . Similarly, in the presence of tamoxifen (1 lm), ADAM12-L levels were also significantly higher in tamoxifen-resistant clones MCF-T17 (2-fold increase) and MCF-T52 (9-fold; P B 0.05) (Fig. 6b) . Taken together, the data suggest that the upregulation of ADAM12 expression may be the mechanism by which antiestrogen-resistant breast tumor cells bypass the growth inhibitory effects of estrogen inhibitors. 
Discussion
The authors have previously reported that elevated levels of urinary ADAM12 are predictive of disease status and stage in breast cancer patients and that ADAM12 protein levels in urine increase with progression of disease [15] . These data suggested an active role for ADAM12 in tumor progression, however, the mechanism(s) by which either ADAM12 isoform might be influencing tumor growth or metastasis remained unknown. In the course of addressing this question, it was observed that ADAM12 expression appears to confer a proliferative advantage to MCF-7 cells in the absence of estrogen. In vitro proliferation rates of ADAM12-L and -S clones were significantly faster than WT MCF-7 in the absence of estrogen. In addition, while WT MCF-7 cells displayed significant growth inhibition when treated with either the ER antagonist tamoxifen or the ER inhibitor ICI 182,780, ADAM12-L and -S clones were significantly less inhibited under the same growth conditions.
The finding that ADAM12 expression confers estrogenindependence to breast tumor cells is novel and potentially When tamoxifen (1 lM) was added to the medium ADAM12-S expression was significantly higher in tamoxifen-resistant clones MCF-T17 (15-fold; *P B 0.05) and MCF-T52 (7.5-fold; *P B 0.05) (a). Similarly, ADAM12-L expression was also upregulated in tamoxifen-resistant clones MCF-T17 (2-fold increase) and MCF-T52 (9-fold; P B 0.05) (b) important given that hormone independence is a hallmark of aggressive breast cancer. Acquired resistance to endocrine therapy in breast cancer is a clinical challenge. In this study, RTK phosphoproteome analysis indicated an increase in pEGFR and pIGF-1R levels in response to ADAM12 expression. In ADAM12-L-expressing cells, AR shedding was enhanced, and EGFR transcript and protein levels were higher, compared to WT MCF-7 suggesting a positive feed-back loop that may be driving the upregulation of EGFR expression. Importantly, ADAM10 and ADAM17, two known AR sheddases, were not involved in this increased shedding of AR. The authors did not observe any difference in their expression levels in the ADAM12-overexpressing clones. This is the first report to describe ADAM12-mediated shedding of AR and a concomitant increase in EGFR expression and activation which ultimately leads to increased proliferation of breast tumor cells. The importance of the EGFR signaling pathway in the estrogen-independent growth of ADAM12-L expressing cells was highlighted by the effect of EGFR inhibitors AG1478 and PD15035 or MAPK inhibitor U0126, each of which abrogated the antiestrogen resistance in these cells. Upregulation of EGFR and heregulin 2 expression has recently been attributed to acquired resistance of breast cancer cells to the antiestrogen, fulvestrant [5] . Similarly, upregulation of autocrine AR signaling via the EGFR pathway has previously been correlated with cisplatin resistance in breast cancer cells [30] . Androgen-sensitive prostate cancer cells, when continuously exposed to HB-EGF, another EGF ligand, proliferate independently of androgen signaling [31] . Therefore, the increased shedding of AR by ADAM12-L could be the potential mechanism by which this protease confers estrogen-independent proliferation in breast tumor cells.
Interestingly, the authors detected an upregulation of ADAM12-L and -S expression in tamoxifen-resistant MCF-7 cells when these cells were treated with the antiestrogen. This finding is consistent with the in vitro data and suggests that the upregulation of ADAM12 expression and increased AR shedding leads to a switch to EGFR signaling that may rescue estrogen dependent MCF-7 cells from the growth inhibitory effects of estrogen inhibitors such as tamoxifen.
Endogenous EGFR expression has been reported to be low in WT MCF-7 cells [28, 32, 33] . In ADAM12-Lexpressing MCF-7 cells, however, both EGFR protein and mRNA levels were significantly elevated. This effect on EGFR expression was also recapitulated in ADAM12-expressing T47-D cells, another ERa positive breast tumor cell line. Consistent with these results for MCF-7, pooled T47-D clones expressing ADAM12-S displayed less growth inhibition in the presence of ICI 182,780 as compared to WT T47-D (Suppl. Fig. 1e ). ADAM12 expression has not previously been correlated with enhanced cancer cell proliferation although its effect on proliferation of normal cells has been reported. For example, ADAM12 was reported to regulate bronchial epithelial cell proliferation and apoptosis in a HB-EGF and EGFR-dependent manner [34] . In osteoarthritis, ADAM12-L has been reported to enhance chondrocyte proliferation via the degradation of IGFBP-5 and increased bioavailability of IGF [35] . The data in this study represents the first demonstration that ADAM12-L overexpression in tumor cells can be directly linked to upregulation of EGFR mRNA and protein expression and downstream MAPK activation and cellular proliferation.
Interestingly, it was found that although the ADAM12-S-expressing cells display increased AR shedding, there does not appear to be a concomitant upregulation of EGFR protein or mRNA expression or activation. Instead, the data suggest that ADAM12-S expression in breast tumor cells may lead to activation of IGF-1R and MAPK resulting in increased proliferation. Mammary stromal and breast cancer cells are known to express IGFs and IGFBPs [36] . ADAM12-S cleaves IGFBP-3 and -5 [14] such that one might speculate that increased bioavailability of free IGF could result in increased activation of IGF-1R and increased proliferation of breast tumor cells in this model.
Taken together, the data in this study suggests that overexpression of either transmembrane or secreted isoforms of ADAM12 results in estrogen-independent growth in breast tumor cells. Wild type MCF-7 proliferation primarily depends on ERa signaling, expression of ADAM12 isoforms appears to allow a switch to EGFR and/or IGF-1R signaling in these cells, thereby rescuing MCF-7 cells from growth inhibition in the absence of estrogen or presence of antiestrogens in vitro ultimately resulting in increased tumor growth in vivo.
This study suggests a potentially novel role for ADAM12 in breast tumor resistance to antiestrogen therapy regimens via the upregulation of alternate growth pathways. Although further studies are required to establish a correlation between ADAM12 function and antiestrogen resistance, targeting ADAM12 and EGFR and/or IGF-1R pathways in combination with hormone therapy may represent a novel approach to address antiestrogen resistance in human breast cancer.
Conclusions
In conclusion, the authors have shown that expression of ADAM12 transmembrane and secreted isoforms confer estrogen-independent growth capabilities in breast tumor cells via distinct mechanisms. In ADAM12-L-expressing cells, this estrogen-independence was a direct result of increased EGFR expression and MAPK activation, whereas, the mechanism in ADAM12-S-expressing cells may be enhanced IGF-1R signaling. Taken together, the data suggest a novel role of ADAM12 in mediating antiestrogen-resistance in breast tumor cells and that targeting ADAM12 in combination with hormone therapy, alone or along with EGFR and/or IGF-1R pathways, may represent a novel approach to address antiestrogen resistance in human breast cancer.
